CCL2 and colitis: Based on the above observations, we hypothesised that irbesartan ameliorated colitis, fibrosis and colitis-associated tumourigenesis by inhibiting both MCP-1 production and the accumulation of CCR2+ monocytes and fibrocytes in the inflamed colon.